NonTNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 316, Issue 11, 2016, Pages 1172-1180

  Gottenberg, Jacques Eric ^a   Brocq, Olivier ^b   Perdriger, Aleth ^c   Lassoued, Slim ^d   Berthelot, Jean Marie ^e   Wendling, Daniel ^f   Euller Ziegler, Liana ^g   Soubrier, Martin ^h   Richez, Christophe ⁱ   Fautrel, Bruno ^j   Constantin, Arnaud L ^k   Mariette, Xavier ^l   Morel, Jacques ^m   Gilson, Melanie ⁿ   Cormier, Gregoire ^o   Salmon, Jean Hugues ^p   Rist, Stephanie ^q   Liot, Frederic ^r   Marotte, Hubert ^s   Bonnet, Christine ^t   Marcelli, Christian ^u   Sellam, Jeremie ^v   Meyer, Olivier ^w   Solau Gervais, Elisabeth ^x   Guis, Sandrine ^y   Ziza, Jean Marc ^z   Zarnitsky, Charles ^aa   Chary Valckenaere, Isabelle ^ab   Vittecoq, Olivier ^ac   Saraux, Alain ^ad   Pers, Yves Marie ^m   Gayraud, Martine ^ae   Bolla, Gilles ^af   Claudepierre, Pascal ^ag   Ardizzone, Marc ^ah   Dernis, Emmanuelle ^ai   Breban, Maxime A ^aj   Fain, Olivier ^v   Balblanc, Jean Charles ^ak   Aberkane, Ouafaa ^al   Vazel, Marion ^al   Back, Christelle ^al   Candon, Sophie ^am   Chatenoud, Lucienne ^am   Perrodeau, Elodie ^an   Sibilia, Jean ^a   Ravaud, Philippe ^an   more..

^a HÔPITAL DE HAUTEPIERRE   (France)

^b CENTRE HOSPITALIER PRINCESSE GRACE   (Monaco)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d Centre Hospitalier de Cahors   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

^g UNIVERSITY HOSPITAL OF NICE   (France)

^h UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁱ BORDEAUX UNIVERSITY HOSPITAL   (France)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k TOULOUSE UNIVERSITY HOSPITAL   (France)

^l BICÊTRE HOSPITAL   (France)

^m MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁿ GRENOBLE UNIVERSITY HOSPITAL   (France)

^o Centre Hospitalier de la Roche sur Yon   (France)

^p REIMS UNIVERSITY HOSPITAL   (France)

^q Centre Hospitalier DOrleans   (France)

^r HÔPITAL LARIBOISIÈRE   (France)

^s UNIVERSITÉ JEAN MONNET   (France)

^t LIMOGES UNIVERSITY HOSPITAL   (France)

^u CAEN UNIVERSITY HOSPITAL   (France)

^v HÔPITAL SAINT ANTOINE   (France)

^w BICHAT HOSPITAL   (France)

^x POITIERS UNIVERSITY HOSPITAL   (France)

^y ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^z GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^aa LE HAVRE HOSPITAL   (France)

^ab UNIVERSITY HOSPITAL OF NANCY   (France)

^ac ROUEN UNIVERSITY HOSPITAL   (France)

^ad BREST UNIVERSITY HOSPITAL   (France)

^ae INSTITUT MUTUALISTE MONTSOURIS   (France)

^af Centre Hospitalier de Cannes   (France)

^ag HENRI MONDOR HOSPITAL   (France)

^ah CENTRE HOSPITALIER DE MULHOUSE   (France)

^ai CENTRE HOSPITALIER DU MANS   (France)

^aj HÔPITAL AMBROISE PARÉ   (France)

^ak Centre Hospitalier de Belfort   (France)

^al UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^am HÔPITAL NECKER ENFANTS MALADES   (France)

^an HÔTEL DIEU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANEMIA; ANOREXIA; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EAR NOSE THROAT DISEASE; EAR NOSE THROAT INFECTION; ERYTHROCYTE SEDIMENTATION RATE; EUROPEAN LEAGUE AGAINST RHEUMATISM SCALE; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; HUMAN; HYPERTENSIVE CRISIS; INFECTIOUS ARTHRITIS; LEUKOCYTIC VASCULITIS; LIMB ISCHEMIA; LUNG ADENOCARCINOMA; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE ASSESSMENT; NEUTROPENIA; OPEN STUDY; OSTEOARTHROPATHY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SKIN INFECTION; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOUS ARTHRITIS; URINARY TRACT INFECTION; VASCULITIS;

EID: 84998828053     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.13512     Document Type: Article

References (19)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-1108.
2. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register. Outcomes after switching from one antitumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56(1):13-20.
3. Hetland ML, Christensen IJ, Tarp U, et al; All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62 (1):22-32.
4. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964-975. doi:10.1136/ard.2009 .126532
5. Cohen SB, Emery P, Greenwald MW, et al; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9): 2793-2806.
6. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516-1523.
7. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-1123.
8. Burmester GR, Blanco R, Charles-Schoeman C, et al; ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013; 381(9865):451-460.
9. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460-1468.
10. Smolen JS, Kay J, Doyle MK, et al; GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009; 374(9685):210-221.
11. Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis. 2014;73(12): 2174-2177.
12. Chatzidionysiou K, van Vollenhoven RF. Rituximab vs anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. Scand J Rheumatol. 2013;42(3):190-195.
13. Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab vs an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2015;74(6):979-984.
14. Finckh A, Ciurea A, Brulhart L, et al; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56(5):1417-1423.
15. Harrold LR, Reed GW, Kremer JM, et al. The comparative effectiveness of abatacept vs anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis. 2015;74(2):430-436.
16. van Gestel AM, Haagsma CJ, van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41(10):1845-1850.
17. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137-145.
18. Baron G, Ravaud P, Samson A, Giraudeau B. Missing data in randomized controlled trials of rheumatoid arthritis with radiographic outcomes: a simulation study. Arthritis Rheum. 2008;59(1):25-31.
19. Twisk J, de Boer M, De Vente W, Heymans M. Multiple imputation of missing values was not necessary before performing a longitudinal mixed-model analysis. J Clin Epidemiol. 2013;66(9): 1022-1028.